Clinical Center; Notice of Closed Meeting
| Published date | 30 September 2021 |
| Citation | 86 FR 54225 |
| Record Number | 2021-21204 |
| Section | Notices |
| Court | National Institutes Of Health |
54225
Federal Register / Vol. 86, No. 187 / Thursday, September 30, 2021 / Notices
opportunities and operational activities
related to SGM health.
The FY 2021–2025 strategic plan
includes the following four scientific
themes and research opportunities:
1. Clinical research
2. Social and behavioral research
3. Research in chronic diseases and
comorbidities
4. Methods and measurement research
Overarching considerations for SGM
research extend to all scientific research
goal areas to help foster a deeper
understanding of SGM health
disparities. Key examples of these
overarching considerations for SGM
research include intersectionality, life
situations, aging, SGM subpopulations,
and relevant research frameworks.
The FY 2021–2025 strategic plan
includes the following four operational
goals:
1. Advance rigorous research on the health
of SGM populations in both the extramural
and intramural research communities;
2. Expand SGM health research by
fostering partnerships and collaborations
with a strategic array of internal and external
stakeholders;
3. Foster a highly skilled and diverse
workforce in SGM health research; and
4. Encourage data collection related to
SGM populations in research and the
biomedical research workforce.
The populations considered under the
SGM umbrella term are inclusive and
capture all individuals and populations
who do not self-identify with binary
constructs of sexual orientation, gender,
and/or sex. Examples of such
populations may include intersex
individuals or individuals with
differences or disorders of sex
development (DSD), Two-Spirit people,
transgender and gender-expansive
people, bisexual people, and
individuals whose gender identity falls
within the full spectrum of gender.
To advance NIH priorities in SGM
health research, SGMRO requests input
from SGM health researchers and
related communities on potential
research opportunities related to the
goals of the FY 2021–2025 strategic
plan.
Responses to this RFI are voluntary.
Do not include any proprietary,
classified, confidential, trade secret, or
sensitive information in your response.
The responses will be reviewed by NIH
staff, and individual feedback will not
be provided to any responder. The
Government will use the information
submitted in response to this RFI at its
discretion. The Government reserves the
right to use any submitted information
on public NIH websites; in reports; in
summaries of the state of the science; in
any possible resultant solicitation(s),
grant(s), or cooperative agreement(s); or
in the development of future funding
opportunity announcements.
This RFI is for information and
planning purposes only and should not
be construed as a solicitation for
applications or proposals, or as an
obligation in any way on the part of the
United States Federal Government, NIH,
or individual NIH Institutes, Centers,
and Offices to provide support for any
ideas identified in response to it. The
federal government will not pay for the
preparation of any information
submitted or for the Government’s use
of such information.
No basis for claims against the U.S.
Government shall arise as a result of a
response to this RFI or from the
Government’s use of such information.
Additionally, the Government cannot
guarantee the confidentiality of the
information provided.
Dated: September 24, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2021–21319 Filed 9–29–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors of the NIH Clinical Center.
The meeting will be closed to the public
as indicated below in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review, discussion,
and evaluation of individual grant
applications conducted by the
CLINICAL CENTER, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors of the NIH Clinical Center.
Date: October 18, 2021.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate
Department of Laboratory Medicine and
interviews.
Place: Clinical Center, 10 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Date: October 19, 2021.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate
Department of Laboratory Medicine and
interviews.
Place: Clinical Center, 10 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ronald Neumann, MD,
Senior Investigation, Clinical Center,
National Institutes of Health, 10 Center Drive,
Bethesda, MD 20892, 301–496–6455,
rneumann@cc.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Dated: September 24, 2021.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2021–21204 Filed 9–29–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Mexico Textile and Apparel Imports
Approved for the Electronic
Certification System (eCERT)
AGENCY
: U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION
: General notice.
SUMMARY
: This document announces
that the certification requirement for
certain imports of textile and apparel
goods from the United Mexican States
(Mexico) that are eligible for preferential
tariff treatment under a tariff preference
level (TPL) will be accomplished
through the Electronic Certification
System (eCERT). Specified quantities of
certain textile and apparel imports from
Mexico that are eligible for preferential
tariff treatment under a TPL must have
a valid certificate of eligibility with a
corresponding eCERT transmission in
order for an importer to claim the
preferential duty rate. As the Agreement
Between the United States of America,
the United Mexican States and Canada
VerDate Sep<11>2014 18:15 Sep 29, 2021 Jkt 253001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\30SEN1.SGM 30SEN1
LOTTER on DSK11XQN23PROD with NOTICES1
